Current Practice of Aranesp in the Management of Haemoglobin Levels : an Observational International Cancer Evaluation

Study Objective

Primary Objective:

To estimate the rate of adherence to EORTC and SPC guidelines on recommended hemoglobin (Hb) values in routine clinical practice use of darbepoetin alfa (Aranesp) in breast, colorectal (CRC), ovarian and lung cancer patients internationally.

Secondary Objective:

Describe treatment practice and transfusion needs in chemotherapy induced anemia patients receiving darbepoetin alfa (Aranesp).

Participation conditions

Inclusion criteria

• Patients > 18 years old.
• Patients receiving darbepoetin alfa (Aranesp) during any cycle of chemotherapy due to symptomatic anemia that have been diagnosed with breast, CRC, ovarian or lung cancer.
• Before any data collection, the appropriate written informed consent must be obtained (where required by local law).

Exclusion criteria

• Patients initiating or having concurrent treatment with any ESA (including darbepoetin alfa (Aranesp)) greater than 4 weeks prior to enrolment (within current chemotherapy course).
• Concurrent participation in any clinical study where the dosing of darbepoetin alfa (Aranesp) is determined by the protocol. Patients may be enrolled in studies if darbepoetin alfa (Aranesp) dosing is at Investigator’s discretion/per SPC and no dosing rules are enforced.
• Any pre-malignant myeloid condition or any other malignancy with myeloid characteristics (e.g. myelodysplastic syndromes, acute or chronic myeloid leukaemia).

Oncologists at Centre Hospitalier de Luxembourg

Oncologists at Centre Hospitalier Emile Mayrisch